Andrei Goga, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Andrei Goga, MD, PhD

Associate Professor of Medicine (Hematology / Oncology), UCSF

Phone: (415) 353-7070 (appts)
Box 1270, UCSF
San Francisco, CA 94143-1270

View on UCSF Profiles

Cancer Center Membership

Program Member » Breast Oncology» Developmental Therapeutics

Education

University of California, Los Angeles, B.S., 1986-1990, Cell and Molecular Biology
University of California, Los Angeles, M.D., 1990-1997, Medicine
University of California, Los Angeles, Ph.D., 1990-1997, Molecular Biology
University of California, San Francisco, 1997-1999, Internal Medicine
University of California, San Francisco, 1999-2003, Medical Oncology


Professional Experience

  • 6/90-5/97
    Medical Scientist Training Program, Univ. of California, Los Angeles.
  • 7/97-6/99
    Internal Medicine Residency, Department of Medicine, University of California, San Francisco.
  • 7/99-8/03
    Medical Oncology Fellow, Division of Hematology/Oncology, UCSF.
  • 9/03-8/05
    Clinical Instructor, Division of Hematology/Oncology, UCSF.
  • 9/05-8/06
    Adjunct Instructor, Division of Hematology/Oncology, UCSF.
  • 9/06-1/07
    Assistant Adjunct Professor, Division of Hematology/Oncology, UCSF.
  • 1/07-6/11
    Assistant Professor, Division of Hematology/Oncology, UCSF.
  • 7/11-Present
    Associate Professor, Division of Hematology/Oncology, UCSF.

Honors & Awards

  • 1990-1997
    N.I.H. Medical Scientist Training Fellowship
  • 1997
    Emil Bogen Research Award, (most outstanding graduate research) UCLA School of Medicine
  • 1997
    UCSF Molecular Medicine Fellow
  • 2001-2004
    Howard Hughes Medical Institute Physician-Scientist Fellowship – NCI K08 Mentored Physician-Scientist Fellowship Award
  • 2008
    Susan G. Komen Scholar Award
  • 2009
    V-Foundation Scholar
  • 2011
    Elected Member of the American Society for Clinical Investigation (ASCI)

Selected Publications

  1. Fas-Activated Mitochondrial Apoptosis Culls Stalled Embryonic Stem Cells to Promote Differentiation. Curr Biol. 2015 Dec 7; 25(23):3110-8.
    View on PubMed
  2. Multiple breast cancer risk variants are associated with differential transcript isoform expression in tumors. Hum Mol Genet. 2015 Dec 20; 24(25):7421-31.
    View on PubMed
  3. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015 Oct 1; 526(7571):131-5.
    View on PubMed
  4. Biogenesis, delivery, and function of extracellular RNA. J Extracell Vesicles. 2015; 4:27494.
    View on PubMed
  5. Identification of Chemical Inhibitors of ß-Catenin-Driven Liver Tumorigenesis in Zebrafish. PLoS Genet. 2015 Jul; 11(7):e1005305.
    View on PubMed
  6. Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemother Pharmacol. 2015 Jul; 76(1):35-46.
    View on PubMed
  7. Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer. ACS Chem Biol. 2015 Jul 17; 10(7):1624-30.
    View on PubMed
  8. CDK1 Inhibition Targets the p53-NOXA-MCL1 Axis, Selectively Kills Embryonic Stem Cells, and Prevents Teratoma Formation. Stem Cell Reports. 2015 Mar 10; 4(3):374-89.
    View on PubMed
  9. Pan-viral-microRNA screening identifies interferon inhibition as a common function of diverse viruses. Proc Natl Acad Sci U S A. 2015 Feb 10; 112(6):1856-61.
    View on PubMed
  10. Linking Tumor Mutations to Drug Responses via a Quantitative Chemical-Genetic Interaction Map. Cancer Discov. 2015 Feb; 5(2):154-67.
    View on PubMed
  11. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 2014 Sep 25; 124(13):2081-90.
    View on PubMed
  12. Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness. ACS Chem Biol. 2014 Jun 20; 9(6):1340-50.
    View on PubMed
  13. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9.
    View on PubMed
  14. Taking on challenging targets: making MYC druggable. Am Soc Clin Oncol Educ Book. 2014; e497-502.
    View on PubMed
  15. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014 Feb; 4(2):232-45.
    View on PubMed
  16. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology. 2014 Jan; 59(1):202-15.
    View on PubMed
  17. A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. Elife. 2013; 2:e00822.
    View on PubMed
  18. Endogenous nuclear RNAi mediates behavioral adaptation to odor. Cell. 2013 Aug 29; 154(5):1010-22.
    View on PubMed
  19. Quantitative measurement of cancer metabolism using stimulated echo hyperpolarized carbon-13 MRS. Magn Reson Med. 2014 Jan; 71(1):1-11.
    View on PubMed
  20. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J. 2012 Nov 1; 447(3):417-25.
    View on PubMed

Go to UCSF Profiles, powered by CTSI